Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

The White House announced the first batch of negotiated Medicare drug prices in August after negotiating for reduced prices for months. The 10 new lower prices — which ranged from a price cut of 79% for Type 2 diabetes drug Januvia to a 38% cut for cancer drug Imbruvica — will go into effect in January 2026.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,